Rituximab: Ongoing and future clinical development

Grillo-López, 2000, Rituximab: The first monoclonal antibody approved for the treatment of lymphoma, Curr Pharm Biotech, 1, 1, 10.2174/1389201003379059

Reff, 1994, Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20, Blood, 83, 435, 10.1182/blood.V83.2.435.435

Anderson, 1997, Targeted anti-cancer therapy using rituximab, a chimeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma, Biochem Soc Trans, 25, 705, 10.1042/bst0250705

Grillo-López, 1999, Overview of the clinical development of rituximab: First monoclonal antibody approved for the treatment of lymphoma, Semin Oncol, 2, 66

Kunkel, 2000, Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: A benefit-risk update, Semin Oncol, 27, 53

2001, Physicians' Desk Reference, 55, 1314

Grillo-López, 2000, Rituximab: An insider's historical perspective, Semin Oncol, 27, 9

McLaughlin, 1998, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a 4-dose treatment program, J Clin Oncol, 16, 2825, 10.1200/JCO.1998.16.8.2825

Piro, 1999, Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma, Ann Oncol, 10, 655, 10.1023/A:1008389119525

Byrd, 2000, Thrice weekly rituximab demonstrates significant activity in chronic lymphocytic leukemia, Blood, 96, 837a

Maloney, 1993, Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma, Blood, 82, 445a

Anhalt, 1990, Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia, N Engl J Med, 323, 1729, 10.1056/NEJM199012203232503

Heizmann, 2001, Successful treatment of PNP in follicular NHL with rituximab, Am J Hematol, 66, 142, 10.1002/1096-8652(200102)66:2<142::AID-AJH1032>3.0.CO;2-0

Hellman, 2001

Davis, 1999, Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab, J Clin Oncol, 17, 1851, 10.1200/JCO.1999.17.6.1851

Davis, 2000, Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of retreatment, J Clin Oncol, 18, 3135, 10.1200/JCO.2000.18.17.3135

Czuczman, 1999, Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy, J Clin Oncol, 17, 268, 10.1200/JCO.1999.17.1.268

Czuczman, 1999, Rituximab/CHOP chemoimmunotherapy in patients (Pts) with low grade lymphoma (LG/F NHL): Progression free survival (PFS) after three years (median) follow up, Blood, 94, 99a

Grillo-López, 2000, Rituximab: Sustained remissions in patients (Pts) with relapsed or refractory low grade or follicular non-Hodgkin's lymphoma (LG/NHL), Blood, 96, 238b

White, 2001, Antibody-targeted immunotherapy for treatment of malignancy, Ann Rev Med, 52, 125, 10.1146/annurev.med.52.1.125

Coiffier, 2000, MabThera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): Interim results of a randomized GELA trial, Blood, 96, 223a

Saleh, 2000, A pilot study of anti-CD20 MoAb rituximab in patients with refractory immune thrombocytopenic purpura (ITP), Blood, 96, 252a

Edwards, 2001, Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes, Rheumatology, 40, 205, 10.1093/rheumatology/40.2.205

Hainsworth, 2000, Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma, Blood, 95, 3052, 10.1182/blood.V95.10.3052

Byrd, 2000, Thrice weekly rituximab demonstrates significant activity in chronic lymphocytic leukemia, Blood, 96, 837a

Bussel, 2000, Overview of idiopathic thrombocytopenic purpura: New approach to refractory patients, Semin Oncol, 27, 91

Saleh, 2000, A pilot study of anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia, Semin Oncol, 27, 99